Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer Article

Industry Collaboration

cited authors

  • Gerber, David E.; Socinski, Mark A.; Neal, Joel W.; Wakelee, Heather A.; Shirai, Keisuke; Sequist, Lecia V.; Rosovsky, Rachel P.; Lilenbaum, Rogerio C.; Bastos, Bruno R.; Huang, Chao; Johnson, Melissa L.; Hesketh, Paul J.; Subramaniam, Deepa S.; Dietrich, Martin F.; Chai, Feng; Wang, Yunxia; Kazakin, Julia; Schwartz, Brian; Schiller, Joan H.; Brahmer, Julie R.; Kelly, Ronan J.

authors

Publication Date

  • March 1, 2018

webpage

published in

category

keywords

  • Adenocarcinoma
  • MET
  • Small molecule
  • Targeted therapy
  • Tyrosine kinase inhibitor

start page

  • 44

end page

  • 49

volume

  • 117